Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02961881 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
A Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 17
- Study locations
NCT02961881 is a Phase 1 study of Non-Hodgkin's Lymphoma that has completed, run by Amgen. The registered enrollment target is 35 participants, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (84% lower). The trial reports 17 study locations across 6 states.
The verdict
NCT02961881, a Phase 1 study of Non-Hodgkin's Lymphoma, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 17
- Study locations
Study Summary
Primary Objective: • To evaluate the safety and tolerability of subcutaneous (SC) blinatumomab dose administrations Secondary Objectives: * To determine pharmacokinetics (PK) with continuous intravenous (cIV) and SC administrations * To estimate the maximum tolerated dose (MTD) tested for blinatumomab administered subcutaneously * To determine the incidence of anti-blinatumomab antibody formation following SC administration * To evaluate efficacy response following treatment with SC blinatumomab administration Exploratory Objective: * To determine the pharmacodynamics (PD) time profiles for B-and T-lymphocytes as well as cytokine profiles during SC administration * To evaluate efficacy response following treatment with SC blinatumomab administration using Lugano criteria if positron emission tomography-computed tomography (PET/CT) is used for evaluation
Conditions Studied
Interventions
- DRUG blinatumomab
Study Locations (17)
Other
- Hopital Henri Mondor - Créteil Cedex
- Hopital Saint Louis - Paris
- Universitaetsklinikum Carl Gustav Carus - Dresden
- Universitätsklinikum Frankfurt/Main - Frankfurt am Main
- Universitatsklinikum Ulm - Ulm
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII - Bergamo
- Azienda Ospedaliera Universitaria di Bologna Policlinico S Orsola Malpighi - Bologna
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia - Brescia
- IRCCS Ospedale San Raffaele - Milan
- IRCCS Istituto Clinico Humanitas - Rozzano MI
- Leicester Royal Infirmary - Leicester
Victoria
- Epworth Healthcare - East Melbourne
- St Vincents Hospital Melbourne - Fitzroy
California
- City of Hope National Medical Center - Duarte
Illinois
- Rush University Medical Center - Chicago
New Jersey
- Hackensack University Medical Center - Hackensack
New South Wales
- Concord Repatriation General Hospital - Concord
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-09-18 |
| Est. Completion | 2021-09-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02961881
The ClinicalTrials.gov registry entry for NCT02961881 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (84% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which blinatumomab is the first listed.
NCT02961881 reports 17 study locations spanning 6 distinct geographic areas - top geographies include Other, Victoria, California.
Frequently Asked Questions
What is clinical trial NCT02961881 about?
NCT02961881 is a clinical study titled "A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma". Primary Objective: • To evaluate the safety and tolerability of subcutaneous (SC) blinatumomab dose administrations Secondary Objectives: * To determine pharmacokinetics (PK) with continuous intravenous (cIV) and SC administrations * To estimate the maximum tolerated dose (MTD) tested for blinatu...
What is the current status of trial NCT02961881?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2017-09-18. Estimated completion is 2021-09-02.
What conditions does trial NCT02961881 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT02961881?
The interventions under investigation include: blinatumomab (DRUG).
Who is sponsoring clinical trial NCT02961881?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02961881 being conducted?
This trial has 17 study locations across California, Illinois, New Jersey, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
RECRUITING · Phase 1
-
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RECRUITING · Phase 1
-
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.